English  |  正體中文  |  简体中文  |  总笔数 :2823698  
造访人次 :  30510740    在线人数 :  872
教育部委托研究计画      计画执行:国立台湾大学图书馆
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
关于TAIR

浏览

消息

著作权

相关连结

"liao w y"的相关文件

回到依作者浏览
依题名排序 依日期排序

显示项目 76-100 / 352 (共15页)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目

机构 日期 题名 作者
臺大學術典藏 2021-11-03T02:33:02Z Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; JIN-YUAN SHIH; Yu C.-J.; Soo R.A.; Yang J.C.-H.
臺大學術典藏 2021-10-04T07:15:42Z Psychological distress and coping strategies among women with incurable lung cancer: a qualitative study Liao Y.-C.; Liao W.-Y.; Sun J.-L.; JEN-CHANG KO; Yu C.-J.
臺大學術典藏 2021-10-04T07:15:41Z Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study Liang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y.
臺大學術典藏 2021-09-17T05:58:15Z Augmented renal clearance is associated with inadequate antibiotic pharmacokinetic/ pharmacodynamic target in Asian ICU population: a prospective observational study Wu C.-C.; CHIH-HSUN TAI; Liao W.-Y.; Wang C.-C.; Kuo C.-H.; Lin S.-W.; Ku S.-C.
臺大學術典藏 2021-09-17T05:56:09Z Prospective evaluation of procalcitonin, soluble triggering receptor expressed on myeloid cells-1 and c-reactive protein in febrile patients with autoimmune diseases Lin C.-H.; Hsieh S.-C.; LI-TA KENG; Lee H.-S.; Chang H.-T.; Liao W.-Y.; Ho C.-C.; Yu C.-J.
臺大學術典藏 2021-09-17T05:41:27Z Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis Chen L.-Y.; Molina-Vila M.A.; Ruan S.-Y.; Su K.-Y.; Liao W.-Y.; KAI-LUN YU; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.H.; Rosell R.; Yang P.-C.
臺大學術典藏 2021-09-17T05:41:26Z The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer KAI-LUN YU; Tsai T.-H.; Ho C.-C.; Liao W.-Y.; Lin C.-K.; Hsu C.-L.; Shih J.-Y.
臺大學術典藏 2021-09-17T03:21:18Z Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study SHENG-KAI LIANG; Lee M.-R.; Liao W.-Y.; Ho C.-C.; Ko J.-C.; Shih J.-Y.
臺大學術典藏 2021-09-17T02:50:57Z Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study Liang S.-K.; MENG-RUI LEE; Liao W.-Y.; Ho C.-C.; Ko J.-C.; Shih J.-Y.
臺大學術典藏 2021-09-09T05:25:29Z Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib ZONG-HAN YAO; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J.
臺大學術典藏 2021-09-09T05:25:27Z Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients ZONG-HAN YAO; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2021-08-31T03:33:45Z Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan SHU-YUNG LIN; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J.
臺大學術典藏 2021-08-24T00:33:34Z Risk Factors of Pneumothorax after Endobronchial Ultrasound-Guided Transbronchial Biopsy for Peripheral Lung Lesions Huang C.-T.; Ruan S.-Y.; Liao W.-Y.; YAO-WEN KUO; Lin C.-Y.; Tsai Y.-J.; Ho C.-C.; Yu C.-J.
臺大學術典藏 2021-08-20T08:00:40Z Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan Lin S.-Y.; Yang C.-Y.; BIN-CHI LIAO; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J.
臺大學術典藏 2021-08-20T08:00:39Z Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; BIN-CHI LIAO; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2021-08-20T08:00:38Z Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; BIN-CHI LIAO; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2021-08-20T08:00:38Z Exon 16�VSkipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M�VPositive Non�VSmall Cell Lung Cancer Hsu C.-C.; BIN-CHI LIAO; Liao W.-Y.; Markovets A.; Stetson D.; Thress K.; Yang J.C.-H.
臺大學術典藏 2021-08-20T08:00:38Z Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC BIN-CHI LIAO; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H.
臺大學術典藏 2021-08-11T03:46:38Z Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.H.; Yu C.-J.
臺大學術典藏 2021-08-11T03:46:37Z Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2021-08-11T03:46:37Z Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; ZHONG-ZHE LIN; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2021-07-13T06:04:33Z Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; LEE JIH-HSIANG; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.
臺大學術典藏 2021-07-13T06:04:33Z Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; LEE JIH-HSIANG; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J.
臺大學術典藏 2021-07-13T06:04:32Z Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non�VSmall-cell Lung Cancer Patients Wu T.-H.; Hsiue E.H.-C.; LEE JIH-HSIANG; Lin C.-C.; Liao W.-Y.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H.
臺大學術典藏 2021-07-13T06:04:31Z Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; LEE JIH-HSIANG; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.

显示项目 76-100 / 352 (共15页)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目